Literature DB >> 18769474

Proline affects brain function in 22q11DS children with the low activity COMT 158 allele.

Jacob A S Vorstman1, Bruce I Turetsky, Monique E J Sijmens-Morcus, Monique G de Sain, Bert Dorland, Mirjam Sprong, Eric F Rappaport, Frits A Beemer, Beverly S Emanuel, René S Kahn, Herman van Engeland, Chantal Kemner.   

Abstract

The association between the 22q11.2 deletion syndrome (22q11DS) and psychiatric disorders, particularly psychosis, suggests a causal relationship between 22q11DS genes and abnormal brain function. The genes catechol-O-methyl-transferase (COMT) and proline dehydrogenase both reside within the commonly deleted region of 22q11.2. COMT activity and proline levels may therefore be altered in 22q11DS individuals. Associations of both COMT(158) genotype and elevated serum proline levels with abnormal brain function have been reported. Fifty-six 22q11DS children and 75 healthy controls were assessed on physiological measures of brain function, including prepulse inhibition (PPI) of startle, P50 auditory sensory gating and smooth pursuit eye movements (SPEM). COMT(158) genotype and plasma proline levels were determined in the 22q11DS children. We hypothesized an interaction between the COMT(158) genotype and proline, predicting the strongest negative effect of high proline on brain function to occur in 22q11DS children who are carriers of the COMT(met) allele. Of the three physiological measures, only SPEM and PPI were abnormal in the patient sample. With regard to the SPEM performance, there was a significant interaction between the COMT(158) genotype and proline level with significantly decreased SPEM performance in children with high plasma proline levels and the low activity COMT(met) allele. A similar interaction effect was not observed with regard to PPI. These findings are consistent with a model in which elevated proline negatively affects brain function by an increase in dopamine in the prefrontal cortex. 22q11DS patients with low dopamine catabolic capacity are therefore especially vulnerable to this functional disruption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769474      PMCID: PMC2817942          DOI: 10.1038/npp.2008.132

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  52 in total

1.  Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain.

Authors:  R T Fremeau; M G Caron; R D Blakely
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

2.  Proline-induced potentiation of glutamate transmission.

Authors:  S M Cohen; J V Nadler
Journal:  Brain Res       Date:  1997-07-04       Impact factor: 3.252

3.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

Authors:  H M Lachman; D F Papolos; T Saito; Y M Yu; C L Szumlanski; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1996-06

4.  Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Authors:  N R Swerdlow; J Paulsen; D L Braff; N Butters; M A Geyer; M R Swenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

5.  Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome.

Authors:  Carrie E Bearden; Abbas F Jawad; David R Lynch; Set Sokol; Steven J Kanes; Donna M McDonald-McGinn; Sulagna C Saitta; Stacy E Harris; Edward Moss; Paul P Wang; Elaine Zackai; Beverly S Emanuel; Tony J Simon
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

6.  NMDA receptor-mediated depolarizing action of proline on CA1 pyramidal cells.

Authors:  D Martin; B Ault; J V Nadler
Journal:  Eur J Pharmacol       Date:  1992-08-14       Impact factor: 4.432

7.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

8.  Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.

Authors:  L E Adler; L J Hoffer; J Griffith; M C Waldo; R Freedman
Journal:  Biol Psychiatry       Date:  1992-10-01       Impact factor: 13.382

9.  Concurrent assessment of acoustic startle and auditory P50 evoked potential measures of sensory inhibition.

Authors:  S B Schwarzkopf; J S Lamberti; D A Smith
Journal:  Biol Psychiatry       Date:  1993 Jun 1-15       Impact factor: 13.382

10.  Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome.

Authors:  Doron Gothelf; Gadi Presburger; Ada H Zohar; Merav Burg; Ariela Nahmani; Moshe Frydman; Mordechai Shohat; Dov Inbar; Ayala Aviram-Goldring; Josepha Yeshaya; Tamar Steinberg; Yehuda Finkelstein; Amos Frisch; Abraham Weizman; Alan Apter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-04-01       Impact factor: 3.568

View more
  39 in total

1.  Long-term proline exposure alters nucleotide catabolism and ectonucleotidase gene expression in zebrafish brain.

Authors:  Luiz Eduardo Baggio Savio; Fernanda Cenci Vuaden; Denis B Rosemberg; Maurício R Bogo; Carla Denise Bonan; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2012-06-07       Impact factor: 3.584

2.  Effects of the val(158)met catechol-O-methyltransferase gene polymorphism on olfactory processing in schizophrenia.

Authors:  Vidyulata Kamath; Paul J Moberg; Raquel E Gur; Richard L Doty; Bruce I Turetsky
Journal:  Behav Neurosci       Date:  2011-12-12       Impact factor: 1.912

3.  Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.

Authors:  Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-25       Impact factor: 5.270

Review 4.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 5.  Bridging the gene-behavior divide through neuroimaging deletion syndromes: Velocardiofacial (22q11.2 Deletion) and Williams (7q11.23 Deletion) syndromes.

Authors:  Daniel Paul Eisenberg; Mbemba Jabbi; Karen Faith Berman
Journal:  Neuroimage       Date:  2010-03-03       Impact factor: 6.556

Review 6.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

7.  PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

Authors:  Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

Review 8.  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia.

Authors:  Maria Karayiorgou; Tony J Simon; Joseph A Gogos
Journal:  Nat Rev Neurosci       Date:  2010-06       Impact factor: 34.870

9.  COMT and anxiety and cognition in children with chromosome 22q11.2 deletion syndrome.

Authors:  Vandana Shashi; Timothy D Howard; Matcheri S Keshavan; Jessica Kaczorowski; Margaret N Berry; Kelly Schoch; Edward J Spence; Thomas R Kwapil
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

Review 10.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.